Daiichi Sankyo helps raise awareness of VTE and AF
13 October 2015 | By Daiichi Sankyo
Daiichi Sankyo has teamed up with World Thrombosis Day to promote awareness of thrombosis, its causes, risk factors, and signs and symptoms...
List view / Grid view
News
Data on Eisai’s eribulin and lenvatinib presented at DGHO
13 October 2015 | By Victoria White
Five abstracts have highlighted the use of Eisai’s eribulin and lenvatinib in rare cancers at the German Association of Hematology and Oncology Meeting...
Bowel cancer can be divided into four distinct diseases
13 October 2015 | By Victoria White
Researchers have shown the bowel cancer can be assigned into different "consensus molecular subtypes"...
Quotient Clinical CEO Mark Egerton a winner at UK EY Entrepreneur of the Year 2015 awards
13 October 2015 | By Quotient Clinical
Quotient Clinical has announced that CEO Mark Egerton has received an EY Entrepreneur of the Year® 2015 UK Award...
CPhI experts warn USA trade laws are too heavily in favour of big pharma
13 October 2015 | By Victoria White
The findings come from the third part of the CPhI Worldwide 2015 annual report (entitled: ‘Push-pull factors on growth’)...
Lilly discontinues development of evacetrapib due to insufficient efficacy
12 October 2015 | By Victoria White
Lilly has said that it will conclude studies of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease...
FDA approves Opdivo for metastatic non-squamous NSCLC
12 October 2015 | By Victoria White
In a Phase 3 trial, Opdivo demonstrated superior overall survival (OS) in previously treated metastatic non-squamous NSCLC compared to chemotherapy...
SMC accepts six new medicines for use by NHS Scotland
12 October 2015 | By Victoria White
The medicines accepted by the SMC include Herceptin for stomach cancer, radium 223 (Xofigo) and abiraterone (Zytiga) for prostate cancer, and nintedanib (Ofev) for idiopathic pulmonary fibrosis
Black Swan Analysis shortlisted for Growing Business Award
12 October 2015 | By Black Swan Analysis
Black Swan Analysis has been shortlisted as the 'Micro Business of the Year' for the 2015 Growing Business Awards...
Data show denosumab achieves greater bone mineral density gains
12 October 2015 | By Victoria White
Results from a Phase 4 study show that denosumab achieved greater gains in bone mineral density than zoledronic acid in postmenopausal women with osteoporosis...
Cosentyx demonstrates sustained efficacy in plaque psoriasis
12 October 2015 | By Victoria White
Cosentyx is the first fully human interleukin-17A (IL-17A) inhibitor approved in Europe and the US to treat adult moderate-to-severe plaque psoriasis...
Lilly acquires rights to hypoglycaemia rescue treatment
12 October 2015 | By Victoria White
Intranasal glucagon, currently in Phase III trials, uses a glucagon nasal powder formulation that is delivered in an emergency situation...
#CPhIChat returns to CPhI Worldwide for the second successive year
9 October 2015 | By Victoria White
#CPhIChat is an industry-wide Tweetchat for pharma professionals working across the supply chain, aimed to stimulate conversations on key industry issues...
Another NICE recommendation for melanoma drug Keytruda
9 October 2015 | By Victoria White
This new recommendation for Keytruda is for treating advanced melanoma that has not been previously treated with ipilimumab...
Verastem reduces its workforce by 50%
9 October 2015 | By Victoria White
Verastem’s announcement comes just weeks after the company had to abandon enrolment in a Phase 2 study of its lead cancer drug VS-6063...
